Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prexasertib in Advanced Solid Tumors with Replicative Stress or HR Deficiency
NCT02873975Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Oct 2016
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of prexasertib in solid tumor (advanced stage) (3 cohorts), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Progression-Free Rate at 4 Month. Started Oct 2016; status: completed.
02
Drugs
prexasertib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02873975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02873975.